- Previous Close
52.40 - Open
60.00 - Bid 52.40 x --
- Ask 60.00 x --
- Day's Range
60.00 - 60.00 - 52 Week Range
0.19 - 60.00 - Volume
100 - Avg. Volume
23,341 - Market Cap (intraday)
6.653M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.69 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 7, 2019
- 1y Target Est
--
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings Ltd was incorporated in 2005 and is based in Jerusalem, Israel.
www.hbl.co.ilRecent News: HDST-M.TA
View MorePerformance Overview: HDST-M.TA
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HDST-M.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HDST-M.TA
View MoreValuation Measures
Market Cap
5.83M
Enterprise Value
2.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
213.54
Price/Book (mrq)
2.08
Enterprise Value/Revenue
76.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.46%
Return on Equity (ttm)
-111.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.66M
Diluted EPS (ttm)
-0.69
Balance Sheet and Cash Flow
Total Cash (mrq)
5.47M
Total Debt/Equity (mrq)
59.03%
Levered Free Cash Flow (ttm)
-1.03M